Currently, the most important therapeutic approaches in the acute phase of ischemic stroke are focused on the restoration of regional cerebral blood flow, early admission to a stroke unit and the attempt to block, using neuroprotective drugs, the biochemical and metabolic changes involved in the ‘ischemic cascade’. Treatment with rt-PA in the acute phase, although very effective, is still limited to a small number of patients and positive preclinical results of neuroprotective treatment have not, as yet, been endorsed in clinical trials. The remarkable lack of concordance between the positive results in experimental models and the negative results obtained in clinical trials has led to a change in attitude in the conduct of preclinical studies as well as to a modification of the design of clinical trials, with special attention being paid to patient selection criteria and clinical evaluation. Some neuroprotective drugs, such as citicoline, have shown some efficacy in subgroups of patients with cerebral infarction, even with a therapeutic window of up to 24 h, which would suggest a possible neurorestorative effect. Different degrees of functional recovery, weeks or months after the ischemic event, are currently observed in clinical practice and have been related to endogenous self-repair mechanisms. The growing understanding of the mechanisms involved in the phenomena of brain plasticity and their modulation, together with the possibility of restoring functional deficits by encouraging endogenous neurogenesis or by cell therapy, open up new directions in the treatment of stroke patients.

Keywords:
Neuroprotection, Neurorestoration, Neuroplasticity, Ischemic stroke, Cell implants, Stem cells, Neurogenesis, Detrimental drugs, Rehabilitation
1.
World Health Organization: The World Health Report 1999. Geneva, Switzerland, WHO, 1999.
2.
Alonso de Leciñana C, Perez R, Diez-Tejedor E: Recommendations for stroke treatment and prevention, 2004. Rev Neurol 2004;39:465–486.
3.
Hankey GJ, Warlow CP: Treatment and secondary prevention of stroke: evidence, costs, and effects on individuals and populations. Lancet 1999;354:1457–1463.
4.
Martinez-Vila E, Irimia P: The cost of stroke. Cerebrovasc Dis 2004;17(suppl 1):124–129.
5.
Murray CJ, Lopez AD: Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet 1997;349:1498–1504.
6.
Elkins JS, Johnston SC: Thirty-year projections for deaths from ischemic stroke in the United States. Stroke 2003;34:2109–2112.
7.
The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group: Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581–1587.
8.
Schellinger PD, Fiebach JB, Hacke W: Imaging-based decision making in thrombolytic therapy for ischemic stroke: present status. Stroke 2003;34:575–583.
9.
Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P: Antithrombotic and thrombolytic therapy for ischemic stroke: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(suppl 3):S483–S512.
10.
Heuschmann PU, Berger K, Misselwitz B, Hermanek P, Leffmann C, Adelmann M, Buecker-Nott HJ, Rother J, Neundoerfer B, Kolominsky-Rabas PL; German Stroke Registers Study Group; Competence Net Stroke: Frequency of thrombolytic therapy in patients with acute ischemic stroke and the risk of in-hospital mortality: the German Stroke Registers Study Group. Stroke 2003;34:1106–1113.
11.
Katzan IL, Furlan AJ, Lloyd LE, Frank JI, Harper DL, Hinchey JA, Hammel JP, Qu A, Sila CA: Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience. JAMA 2000;283:1151–1158.
12.
Auer RN: Non-pharmacologic (physiologic) neuroprotection in the treatment of brain ischemia. Ann NY Acad Sci 2001;939:271–282.
13.
Martinez-Vila E, Sieira PI: Current status and perspectives of neuroprotection in ischemic stroke treatment. Cerebrovasc Dis 2001;11 (suppl 1):60–70.
14.
Castillo J, Alvarez-Sabin J, Davalos A, Diez-Tejedor E, Lizasoain I, Martinez-Vila E, Vivancos J, Zarranz JJ: Consensus review. Pharmacological neuroprotection in cerebral ischemia: is it still a therapeutic option? Neurologia 2003;18:368–384.
15.
Devuyst G, Bogousslavsky J: Clinical trial update: neuroprotection against acute ischaemic stroke. Curr Opin Neurol 1999;12:73–79.
16.
Labiche LA, Grotta JC: Clinical trials for cytoprotection in stroke. NeuroRx 2004;1:46–70.
17.
Danton GH, Dietrich WD: The search for neuroprotective strategies in stroke. AJNR Am J Neuroradiol 2004;25:181–194.
18.
Muir KW, Lees KR, Ford I, Davis S: Magnesium for acute stroke (Intravenous Magnesium Efficacy in Stroke trial): randomised controlled trial. Lancet 2004;363:439–445.
19.
Cheng YD, Al Khoury L, Zivin JA: Neuroprotection for ischemic stroke: two decades of success and failure. NeuroRx 2004;1:36–45.
20.
Gladstone DJ, Black SE, Hakim AM: Toward wisdom from failure: lessons from neuroprotective stroke trials and new therapeutic directions. Stroke 2002;33:2123–2136.
21.
Grotta J: Neuroprotection is unlikely to be effective in humans using current trial designs. Stroke 2002;33:306–307.
22.
Lees KR: Neuroprotection is unlikely to be effective in humans using current trial designs: an opposing view. Stroke 2002;33:308–309.
23.
Wahlgren NG, Ahmed N: Neuroprotection in cerebral ischaemia: facts and fancies – the need for new approaches. Cerebrovasc Dis 2004;17(suppl 1):153–166.
24.
Grotta J: Why do all drugs work in animals but none in stroke patients? 2. Neuroprotective therapy. J Intern Med 1995;237:89–94.
25.
Seil FJ: Recovery and repair issues after stroke from the scientific perspective. Curr Opin Neurol 1997;10:49–51.
26.
Johansson BB: Brain plasticity and stroke rehabilitation. The Willis lecture. Stroke 2000;31:223–230.
27.
Johansson BB, Grabowski M: Functional recovery after brain infarction: plasticity and neural transplantation. Brain Pathol 1994;4:85–95.
28.
Fisher M, Finklestein S: Pharmacological approaches to stroke recovery. Cerebrovasc Dis 1999;9(suppl 5):29–32.
29.
Haas S, Weidner N, Winkler J: Adult stem cell therapy in stroke. Curr Opin Neurol 2005;18:59–64.
30.
Dirnagl U, Iadecola C, Moskowitz MA: Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci 1999;22:391–397.
31.
Garcia JH, Liu KF, Ye ZR, Gutierrez JA: Incomplete infarct and delayed neuronal death after transient middle cerebral artery occlusion in rats. Stroke 1997;28:2303–2309.
32.
Ginsberg MD, Pulsinelli WA: The ischemic penumbra, injury thresholds, and the therapeutic window for acute stroke. Ann Neurol 1994;36:553–554.
33.
Astrup J, Siesjo BK, Symon L: Thresholds in cerebral ischemia – the ischemic penumbra. Stroke 1981;12:723–725.
34.
Hossmann KA: Viability thresholds and the penumbra of focal ischemia. Ann Neurol 1994;36:557–565.
35.
Heiss WD, Kracht LW, Thiel A, Grond M, Pawlik G: Penumbral probability thresholds of cortical flumazenil binding and blood flow predicting tissue outcome in patients with cerebral ischaemia. Brain 2001;124:20–29.
36.
Chamorro A: The shadow of ischemia. Therapeutic window. Neurologia 1999;14(suppl 4):35–40.
37.
Hacke W, Albers G, Al-Rawi Y, Bogousslavsky J, Davalos A, Eliasziw M, Fischer M, Furlan A, Kaste M, Lees KR, Soehngen M, Warach S; DIAS Study Group: The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 2005;36:66–73.
38.
Wise RJ, Bernardi S, Frackowiak RS, Legg NJ, Jones T: Serial observations on the pathophysiology of acute stroke. The transition from ischaemia to infarction as reflected in regional oxygen extraction. Brain 1983;106:197–222.
39.
Baron JC, von Kummer R, del Zoppo GJ: Treatment of acute ischemic stroke. Challenging the concept of a rigid and universal time window. Stroke 1995;26:2219–2221.
40.
Lutsep HL, Clark WM: Neuroprotection in acute ischaemic stroke. Current status and future potential. Drugs RD 1999;1:3–8.
41.
Neuroprotection as initial therapy in acute stroke. Third Report of an Ad Hoc Consensus Group Meeting. The European Ad Hoc Consensus Group. Cerebrovasc Dis 1998;8:59–72.
42.
Devuyst G, Bogousslavsky J: Recent progress in drug treatment for acute ischemic stroke. Cerebrovasc Dis 2001;11(suppl 1):71–79.
43.
Lindsberg PJ, Roine RO, Tatlisumak T, Sairanen T, Kaste M: The future of stroke treatment. Neurol Clin 2000;18:495–510.
44.
Rossini PM, Calautti C, Pauri F, Baron JC: Post-stroke plastic reorganisation in the adult brain. Lancet Neurol 2003;2:493–502.
45.
Nudo RJ: Adaptive plasticity in motor cortex: implications for rehabilitation after brain injury. J Rehabil Med 2003(suppl 41):7–10.
46.
Butefisch CM, Netz J, Wessling M, Seitz RJ, Homberg V: Remote changes in cortical excitability after stroke. Brain 2003;126:470–481.
47.
Johansson BB, Grabowski M: Functional recovery after brain infarction: plasticity and neural transplantation. Brain Pathol 1994;4:85–95.
48.
Kidwell CS, Liebeskind DS, Starkman S, Saver JL: Trends in acute ischemic stroke trials through the 20th century. Stroke 2001;32:1349–1359.
49.
Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 1999;30:2752–2758.
50.
Recommendations for clinical trial evaluation of acute stroke therapies. Stroke 2001;32:1598–1606.
51.
Alonso de Leciñana M, Diez-Tejedor E, Carceller F, Roda JM: Cerebral ischemia: from animal studies to clinical practice. Should the methods be reviewed? Cerebrovasc Dis 2001;11(suppl 1):20–30.
52.
De Keyser J, Sulter G, Luiten PG: Clinical trials with neuroprotective drugs in acute ischaemic stroke: are we doing the right thing? Trends Neurosci 1999;22:535–540.
53.
Muir KW: Heterogeneity of stroke pathophysiology and neuroprotective clinical trial design. Stroke 2002;33:1545–1550.
54.
Yakovlev AG, Faden AI: Mechanisms of neural cell death: implications for development of neuroprotective treatment strategies. NeuroRx 2004;1:5–16.
55.
Sacchetti ML, Toni D, Fiorelli M, Argentino C, Fieschi C: The concept of combination therapy in acute ischemic stroke. Neurology 1997;49(suppl 4):S70–S74.
56.
Fisher M, Jonas S, Sacco RL, Jones S: Prophylactic neuroprotection for cerebral ischemia. Stroke 1994;25:1075–1080.
57.
Grotta J: Combination therapy stroke trial: recombinant tissue-type plasminogen activator with/without lubeluzole. Cerebrovasc Dis 2001;12:258–263.
58.
Diez-Tejedor E, Fuentes B: Acute care in stroke: do stroke units make the difference? Cerebrovasc Dis 2001;11(suppl 1):31–39.
59.
Davalos A, Castillo J, Alvarez-Sabin J, Secades JJ, Mercadal J, Lopez S, Cobo E, Warach S, Sherman D, Clark WM, Lozano R: Oral citicoline in acute ischemic stroke: an individual patient data pooling analysis of clinical trials. Stroke 2002;33:2850–2857.
60.
Pons TP, Garraghty PE, Ommaya AK, Kaas JH, Taub E, Mishkin M: Massive cortical reorganization after sensory deafferentation in adult macaques. Science 1991;252:1857–1860.
61.
Taub E, Uswatte G, Morris DM: Improved motor recovery after stroke and massive cortical reorganization following Constraint-Induced Movement therapy. Phys Med Rehabil. Clin N Am 2003;14(suppl 1):S77–S91.
62.
Liepert J, Bauder H, Wolfgang HR, Miltner WH, Taub E, Weiller C: Treatment-induced cortical reorganization after stroke in humans. Stroke 2000;31:1210–1216.
63.
Cramer SC, Bastings EP: Mapping clinically relevant plasticity after stroke. Neuropharmacology 2000;39:842–851.
64.
Goldstein LB: Basic and clinical studies of pharmacologic effects on recovery from brain injury. J Neural Transplant Plast 1993;4:175–192.
65.
Goldstein LB: Potential impact of drugs on poststroke recovery; in Goldstein LB (ed): Restorative Neurology: Advances in Pharmacotherapy for Recovery after Stroke. ed 1. Armonk, NY, Futura Publishing Company, 1998, pp 241–256.
66.
Martinsson L, Wahlgren NG, Hardemark HG: Amphetamines for improving recovery after stroke. Cochrane Database Syst Rev 2003(3):CD002090.
67.
Scheidtmann K, Fries W, Muller F, Koenig E: Effect of levodopa in combination with physiotherapy on functional motor recovery after stroke: a prospective, randomised, double-blind study. Lancet 2001;358:787–790.
68.
Marti-Fabregas J, Gomis M, Arboix A, Aleu A, Pagonabarraga J, Belvis R, Cocho D, Roquer J, Rodriguez A, Garcia MD, Molina-Porcel L, Diaz-Manera J, Marti-Vilalta JL: Favorable outcome of ischemic stroke in patients pretreated with statins. Stroke 2004;35:1117–1121.
69.
Chen J, Zhang ZG, Li Y, Wang Y, Wang L, Jiang H, Zhang C, Lu M, Katakowski M, Feldkamp CS, Chopp M: Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke. Ann Neurol 2003;53:743–751.
70.
Goldstein LB: Common drugs may influence motor recovery after stroke. The Sygen In Acute Stroke Study Investigators. Neurology 1995;45:865–871.
71.
Goldstein LB, Davis JN: Physician prescribing patterns following hospital admission for ischemic cerebrovascular disease. Neurology 1988;38:1806–1809.
72.
Carod-Artal J, Egido JA, Gonzalez JL, Varela de Seijas E: Quality of life among stroke survivors evaluated 1 year after stroke: experience of a stroke unit. Stroke 2000;31:2995–3000.
73.
Parent JM, Vexler ZS, Gong C, Derugin N, Ferriero DM: Rat forebrain neurogenesis and striatal neuron replacement after focal stroke. Ann Neurol 2002;52:802–813.
74.
Arvidsson A, Collin T, Kirik D, Kokaia Z, Lindvall O: Neuronal replacement from endogenous precursors in the adult brain after stroke. Nat Med 2002;8:963–970.
75.
Miyai I, Reding M: Effect of antidepressants on functional recovery following stroke: a double-blind study. J Neurorehabil 1998;12:5–13.
76.
Pariente J, Loubinoux I, Carel C, Albucher JF, Leger A, Manelfe C, Rascol O, Chollet F: Fluoxetine modulates motor performance and cerebral activation of patients recovering from stroke. Ann Neurol 2001;50:718–729.
77.
Walker-Batson D, Curtis S, Natarajan R, Ford J, Dronkers N, Salmeron E, Lai J, Unwin DH: A double-blind, placebo-controlled study of the use of amphetamine in the treatment of aphasia. Stroke 2001;32:2093–2098.
78.
Walker-Batson D, Smith P, Curtis S, Unwin H, Greenlee R: Amphetamine paired with physical therapy accelerates motor recovery after stroke. Further evidence. Stroke 1995;26:2254–2259.
79.
Dam M, Tonin P, De Boni A, Pizzolato G, Casson S, Ermani M, Freo U, Piron L, Battistin L: Effects of fluoxetine and maprotiline on functional recovery in poststroke hemiplegic patients undergoing rehabilitation therapy. Stroke 1996;27:1211–1214.
80.
Grade C, Redford B, Chrostowski J, Toussaint L, Blackwell B: Methylphenidate in early poststroke recovery: a double-blind, placebo-controlled study. Arch Phys Med Rehabil 1998;79:1047–1050.
81.
Nudo RJ, Wise BM, SiFuentes F, Milliken GW: Neural substrates for the effects of rehabilitative training on motor recovery after ischemic infarct. Science 1996;272:1791–1794.
82.
Johansen-Berg H, Dawes H, Guy C, Smith SM, Wade DT, Matthews PM: Correlation between motor improvements and altered fMRI activity after rehabilitative therapy. Brain 2002;125:2731–2742.
83.
Thirumala P, Hier DB, Patel P: Motor recovery after stroke: lessons from functional brain imaging. Neurol Res 2002;24:453–458.
84.
Feydy A, Carlier R, Roby-Brami A, Bussel B, Cazalis F, Pierot L, Burnod Y, Maier MA: Longitudinal study of motor recovery after stroke: recruitment and focusing of brain activation. Stroke 2002;33:1610–1617.
85.
Ward NS, Brown MM, Thompson AJ, Frackowiak RS: Neural correlates of outcome after stroke: a cross-sectional fMRI study. Brain 2003;126:1430–1448.
86.
Kwakkel G, Wagenaar RC, Twisk JW, Lankhorst GJ, Koetsier JC: Intensity of leg and arm training after primary middle-cerebral-artery stroke: a randomised trial. Lancet 1999;354:191–196.
87.
Carey JR, Kimberley TJ, Lewis SM, Auerbach EJ, Dorsey L, Rundquist P, Ugurbil K: Analysis of fMRI and finger tracking training in subjects with chronic stroke. Brain 2002;125:773–788.
88.
Weiller C, Chollet F, Friston KJ, Wise RJ, Frackowiak RS: Functional reorganization of the brain in recovery from striatocapsular infarction in man. Ann Neurol 1992;31:463–472.
89.
Teasell R: Stroke recovery and rehabilitation. Stroke 2003;34:365–366.
90.
Werner C, Bardeleben A, Mauritz KH, Kirker S, Hesse S: Treadmill training with partial body weight support and physiotherapy in stroke patients: a preliminary comparison. Eur J Neurol 2002;9:639–644.
91.
Kuest J, Karbe H: Cortical activation studies in aphasia. Curr Neurol Neurosci Rep 2002;2:511–515.
92.
Musso M, Weiller C, Kiebel S, Muller SP, Bulau P, Rijntjes M: Training-induced brain plasticity in aphasia. Brain 1999;122:1781–1790.
93.
Gage FH: Mammalian neural stem cells. Science 2000;287:1433–1438.
94.
Jin K, Minami M, Lan JQ, Mao XO, Batteur S, Simon RP, Greenberg DA: Neurogenesis in dentate subgranular zone and rostral subventricular zone after focal cerebral ischemia in the rat. Proc Natl Acad Sci USA 2001;98:4710–4715.
95.
Kokaia Z, Lindvall O: Neurogenesis after ischaemic brain insults. Curr Opin Neurobiol 2003;13:127–132.
96.
Shingo T, Sorokan ST, Shimazaki T, Weiss S: Erythropoietin regulates the in vitro and in vivo production of neuronal progenitors by mammalian forebrain neural stem cells. J Neurosci 2001;21:9733–9743.
97.
Panchision DM, McKay RD: The control of neural stem cells by morphogenic signals. Curr Opin Genet Dev 2002;12:478–487.
98.
Schanzer A, Wachs FP, Wilhelm D, Acker T, Cooper-Kuhn C, Beck H, Winkler J, Aigner L, Plate KH, Kuhn HG: Direct stimulation of adult neural stem cells in vitro and neurogenesis in vivo by vascular endothelial growth factor. Brain Pathol 2004;14:237–248.
99.
Jin K, Zhu Y, Sun Y, Mao XO, Xie L, Greenberg DA: Vascular endothelial growth factor (VEGF) stimulates neurogenesis in vitro and in vivo. Proc Natl Acad Sci USA 2002;99:11946–11950.
100.
Ehrenreich H, Hasselblatt M, Dembowski C, Cepek L, Lewczuk P, Stiefel M, Rustenbeck HH, Breiter N, Jacob S, Knerlich F, Bohn M, Poser W, Ruther E, Kochen M, Gefeller O, Gleiter C, Wessel TC, De Ryck M, Itri L, Prange H, Cerami A, Brines M, Siren AL: Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 2002;8:495–505.
101.
Wang L, Zhang Z, Wang Y, Zhang R, Chopp M: Treatment of stroke with erythropoietin enhances neurogenesis and angiogenesis and improves neurological function in rats. Stroke 2004;35:1732–1737.
102.
Bjorklund A, Lindvall O: Cell replacement therapies for central nervous system disorders. Nat Neurosci 2000;3:537–544.
103.
Savitz SI, Rosenbaum DM, Dinsmore JH, Wechsler LR, Caplan LR: Cell transplantation for stroke. Ann Neurol 2002;52:266–275.
104.
Kondziolka D, Wechsler L, Achim C: Neural transplantation for stroke. J Clin Neurosci 2002;9:225–230.
105.
Zhang ZG, Jiang Q, Zhang R, Zhang L, Wang L, Zhang L, Arniego P, Ho KL, Chopp M: Magnetic resonance imaging and neurosphere therapy of stroke in rat. Ann Neurol 2003;53:259–263.
106.
Nunes MC, Roy NS, Keyoung HM, Goodman RR, McKhann G 2nd, Jiang L, Kang J, Nedergaard M, Goldman SA: Identification and isolation of multipotential neural progenitor cells from the subcortical white matter of the adult human brain. Nat Med 2003;9:439–447.
107.
Rice CM, Scolding NJ: Adult stem cells – reprogramming neurological repair? Lancet 2004;364:193–199.
108.
Chen J, Li Y, Wang L, Zhang Z, Lu D, Lu M, Chopp M: Therapeutic benefit of intravenous administration of bone marrow stromal cells after cerebral ischemia in rats. Stroke 2001;32:1005–1011.
109.
Willing AE, Vendrame M, Mallery J, Cassady CJ, Davis CD, Sanchez-Ramos J, Sanberg PR: Mobilized peripheral blood cells administered intravenously produce functional recovery in stroke. Cell Transplant 2003;12:449–454.
110.
Taguchi A, Soma T, Tanaka H, Kanda T, Nishimura H, Yoshikawa H, Tsukamoto Y, Iso H, Fujimori Y, Stern DM, Naritomi H, Matsuyama T: Administration of CD34+ cells after stroke enhances neurogenesis via angiogenesis in a mouse model. J Clin Invest 2004;114:330–338.
111.
Wechsler LR, Kondziolka D: Cell therapy: replacement. Stroke 2003;34:2081–2082.
112.
Kondziolka D, Wechsler L, Goldstein S, Meltzer C, Thulborn KR, Gebel J, Jannetta P, DeCesare S, Elder EM, McGrogan M, Reitman MA, Bynum L: Transplantation of cultured human neuronal cells for patients with stroke. Neurology 2000;55:565–569.
113.
Kleppner SR, Robinson KA, Trojanowski JQ, Lee VM: Transplanted human neurons derived from a teratocarcinoma cell line (NTera-2) mature, integrate, and survive for over 1 year in the nude mouse brain. J Comp Neurol 1995;357:618–632.
114.
Meltzer CC, Kondziolka D, Villemagne VL, Wechsler L, Goldstein S, Thulborn KR, Gebel J, Elder EM, DeCesare S, Jacobs A: Serial [18F] fluorodeoxyglucose positron emission tomography after human neuronal implantation for stroke. Neurosurgery 2001;49:586–591.
115.
Bang OY, Lee JS, Lee PH, Lee G: Autologous mesenchymal stem cell transplantation in stroke patients. Ann Neurol 2005;57:874–872.
© 2005 S. Karger AG, Basel
2005
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.